Business
Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management
PALO ALTO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating
About this update from Scilex Holding Company
[{"type":"text","content":"PALO ALTO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has signed a non-binding, non-exclusive Memorandum of Understanding (the “MOU”) with Biconomy.com (“Biconomy”) with respect to future cryptocurrency and treasury management strategies, including in the following areas: (1) Collaborating and leveraging Biconomy’s cryptocurrency exchange platform to provide global cryptocurrency trading services for Scilex’s digital assets, which could potentially excess a billion dollars per cryptocurrency, including Bitcoins, Ethereum, and other major cryptocurrencies.(2) Establishing a cryptocurrency treasury management strategy at Scilex with a balance in security, liquidity, compliance, and yield. (3) Leveraging technology provided by Biconomy.com to deliver to Scilex financial and trade information in order to monetize Scilex’s digital assets. “We are thrilled to be collaborating with Scilex on crypto strategies in order to create long-term value in their digital assets and to accelerate the shift toward a crypto-powered economy,” said Dmitry Sheludko, CEO of Biconomy.com. For more information on Scilex Holding Company, refer to www.scilexholding.com. For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com. For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com. For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com. For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com. https://www.facebook.com/scilex.pharm https://www.linkedin.com/company/scilex-holding-company/ [email protected] About Scilex Holding Company Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of pat...